Spots Global Cancer Trial Database for oral chemotherapy
Every month we try and update this database with for oral chemotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Mobile Application to Assist Adherence to Oral Anticancer Agents and Symptom Management | NCT04626830 | Cancer Adherence to Me... Symptom Managem... | Mobile Applicat... | 18 Years - | Baskent University | |
| A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. | NCT00676299 | Protein Kinase ... Antineoplastic ... Clinical Trial,... Maximum Tolerat... Pharmacokinetic... Advanced Malign... Solid Malignanc... | JNJ-26483327 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Patient Factors Impacting Adherence to Oral Chemotherapy | NCT01487343 | Breast Cancer Gastrointestina... | questionnaire a... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | NCT03952325 | Breast Cancer | Tesetaxel Tesetaxel Tesetaxel Nivolumab Pembrolizumab Atezolizumab Tesetaxel | 18 Years - | Odonate Therapeutics, Inc. | |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | NCT00994071 | Medulloblastoma Pontine Glioma Ependymoma Astrocytoma PNET | Temozolomide ABT-888 | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca | NCT02144194 | Breast Cancer | Vinorelbine-Doc... Vinorelbine | 18 Years - | Cancer Research Group - Collaborative Group, Beirut, Lebanon. | |
| Mobile Application to Assist Adherence to Oral Anticancer Agents and Symptom Management | NCT04626830 | Cancer Adherence to Me... Symptom Managem... | Mobile Applicat... | 18 Years - | Baskent University | |
| Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer | NCT02157519 | Adherence to Me... Cancer | Mobile Applicat... | 18 Years - | Massachusetts General Hospital | |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | NCT00644189 | Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Small Lymphocyt... Lymphoplasmacyt... Low Grade B-cel... Diffuse Large B... Peripheral T-ce... Angioimmunoblas... Anaplastic Larg... | Clofarabine | 18 Years - | Massachusetts General Hospital | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma | NCT02240771 | Hepatocellular ... | Transarterial c... Oral chemothera... | 12 Years - 80 Years | All India Institute of Medical Sciences, New Delhi | |
| Medico-economic Evaluation of the ONCORAL Program for Ambulatory Patients Under Oral Anticancer Drugs Versus Usual Care | NCT03660670 | Cancer | ONCORAL therape... Standard of car... | 18 Years - | Hospices Civils de Lyon | |
| Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer | NCT02849535 | Metastatic Rena... | PRISM care prog... | 18 Years - | Hospices Civils de Lyon | |
| MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | NCT00403429 | Ovarian Cancer | capecitabine | - 75 Years | National Cancer Institute, Naples | |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | NCT00644189 | Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Small Lymphocyt... Lymphoplasmacyt... Low Grade B-cel... Diffuse Large B... Peripheral T-ce... Angioimmunoblas... Anaplastic Larg... | Clofarabine | 18 Years - | Massachusetts General Hospital | |
| Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC | NCT03952325 | Breast Cancer | Tesetaxel Tesetaxel Tesetaxel Nivolumab Pembrolizumab Atezolizumab Tesetaxel | 18 Years - | Odonate Therapeutics, Inc. | |
| Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric Cancer | NCT03822130 | Successful Conv... Unresectable Ga... | Arterial cathet... Sodium Bicarbon... Systemic Chemot... Oral Chemothera... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | NCT00994071 | Medulloblastoma Pontine Glioma Ependymoma Astrocytoma PNET | Temozolomide ABT-888 | - 21 Years | National Institutes of Health Clinical Center (CC) | |
| Evaluation of Patients' Satisfaction With the Dispensation of Their Oral Anticancer Treatment in Community Pharmacy | NCT03275675 | Cancer | Oral anticancer... | 18 Years - | University Hospital, Clermont-Ferrand |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
